<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002547</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000063305</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-696-87</secondary_id>
    <secondary_id>NCI-V93-0345</secondary_id>
    <nct_id>NCT00002547</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with bone marrow transplantation may&#xD;
      allow the doctor to give higher doses of chemotherapy and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation following&#xD;
      combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic&#xD;
      syndrome .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine overall and leukemia-free survival of patients with acute&#xD;
      nonlymphocytic leukemia or myelodysplastic syndrome treated with busulfan and&#xD;
      cyclophosphamide (low-risk patients) or cytarabine, busulfan, and cyclophosphamide (high-risk&#xD;
      patients) followed by allogeneic or syngeneic bone marrow transplantation. II. Compare the&#xD;
      therapeutic effects of these cytoreduction regimens with those reported in the literature for&#xD;
      similar patients who undergo syngeneic or allogeneic marrow transplantation following&#xD;
      cytoreduction that includes total-body irradiation. III. Determine the early and late toxic&#xD;
      effects produced by these chemotherapy regimens in this patient population.&#xD;
&#xD;
      OUTLINE: Low-risk patients (those in first complete remission (CR) who achieved CR with 1&#xD;
      course of chemotherapy) are treated on Regimen A. High-risk patients (those in second or&#xD;
      subsequent CR who required more than 1 course of chemotherapy to achieve first CR or those&#xD;
      with myelodysplastic syndrome) are treated on Regimen B. All patients undergo diagnostic&#xD;
      lumbar puncture prior to beginning therapy and fluid is examined for CNS disease. Patients&#xD;
      receive methotrexate IT along with the tap. Prior to initiation of chemotherapy, patients&#xD;
      with CNS disease present on diagnostic lumbar puncture receive methotrexate IT every 2-3 days&#xD;
      until lumbar puncture shows no leukemia cells and then 1 additional dose. Cytoreductive&#xD;
      chemotherapy begins 3 days after the last dose of methotrexate. Regimen A: Patients receive&#xD;
      oral busulfan every 6 hours on days -7 to -4 for a total of 16 doses and cyclophosphamide IV&#xD;
      over 2 hours on days -3 and -2. Allogeneic bone marrow is infused on day 0. Regimen B:&#xD;
      Patients receive oral busulfan every 6 hours on days -9 to -6 for a total of 16 doses.&#xD;
      Patients receive cytarabine IV over 1 hour every 12 hours on days -5 and -4 and&#xD;
      cyclophosphamide IV over 2 hours on days -3 and -2. Allogeneic bone marrow is infused on day&#xD;
      0. Graft versus host disease prophylaxis: Patients receive cyclosporine IV continuously on&#xD;
      days -1 to 28 followed by a taper of oral cyclosporine until day 180. Patients receive&#xD;
      methotrexate IV on days 1, 3, 6, and 11. CNS disease prophylaxis: Patients receive 5 more&#xD;
      doses of methotrexate IT weekly beginning between days 50 and 70. In addition, patients with&#xD;
      history of CNS disease receive 1 dose of methotrexate IT monthly for 1 year. Patients are&#xD;
      followed frequently during the first 100 days, at 6 months, 1 year, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2.7 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1987</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">280</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <other_name>Busulfex®</other_name>
    <other_name>Myleran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>Sangcya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <other_name>DepoCytTM</other_name>
    <other_name>Liposomal Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <other_name>Rheumatrex®</other_name>
    <other_name>TrexallTM</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Methotrexate Sodium</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>syngeneic bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: The following hematologic malignancies are eligible: Acute&#xD;
        nonlymphocytic leukemia in one of the following categories: In complete remission In early&#xD;
        relapse Newly diagnosed FAB types M6 and M7 Myelodysplastic syndromes including: Refractory&#xD;
        anemia with excessive blasts Refractory anemia with excessive blasts in transformation&#xD;
        Chronic myelomonocytic leukemia Secondary acute myeloid leukemia Transplantation priority&#xD;
        given in decreasing order of: First remission Second remission Third remission Early&#xD;
        relapse, with priority further reduced for: Refractory response to platelet transfusion&#xD;
        Severe infection within 6 weeks prior to referral History of major organ pathology or&#xD;
        insult (hepatitis, renal damage, pulmonary disease, cystitis, etc.) CNS disease allowed but&#xD;
        priority status for transplantation lowered Donor Criteria: Sibling or matched&#xD;
        related/unrelated donor required Donor priority as follows: Monozygotic twin Genotypical or&#xD;
        phenotypical HLA-A, -B, -C, and -D match Match at any 2 loci (A, B, Dr) on the other&#xD;
        haplotype ABO-compatible donor preferred Marrow processed to eliminate mismatched&#xD;
        erythrocytes if ABO incompatible In case of multiple donors, priority is: ABO compatibility&#xD;
        Age over 18 Same sex No physiologic, psychologic, or medical contraindication to donation&#xD;
        procedure No increased anesthetic risk due to pre-existing illness HIV negative&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 6 months to 60 years Performance status: No preterminal or&#xD;
        moribund patients Life expectancy: No severe limits on life expectancy due to diseases&#xD;
        other than leukemia Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no&#xD;
        greater than 2.0 mg/dL Transaminases no greater than 3 times normal No severe hepatic&#xD;
        disease Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60&#xD;
        mL/min No severe renal disease No history of severe cystitis with cyclophosphamide&#xD;
        Cardiovascular: LVEF at least 50% No symptomatic cardiac disease Pulmonary: FEV1 and FVC at&#xD;
        least 75% of normal No severe pulmonary disease Other: HIV negative No severe personality&#xD;
        disorder or severe mental illness No condition (such as substance abuse) that would&#xD;
        markedly increase the morbidity and mortality of transplantation Criteria of hepatic,&#xD;
        renal, cardiac, and pulmonary function and mental illness are used only for initial&#xD;
        screening of potential candidates; patients who do not meet these criteria may still be&#xD;
        eligible at the discretion of the transplant team&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esteban Abella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2004</study_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

